scispace - formally typeset
Search or ask a question
Author

Aoife M. Egan

Bio: Aoife M. Egan is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pregnancy & Gestational diabetes. The author has an hindex of 18, co-authored 73 publications receiving 1173 citations. Previous affiliations of Aoife M. Egan include Connolly Hospital Blanchardstown & University College Hospital.


Papers
More filters
Journal ArticleDOI
Denice S. Feig1, Denice S. Feig2, Lois E. Donovan3, Rosa Corcoy, Kellie E. Murphy2, Kellie E. Murphy1, Stephanie A. Amiel4, Katharine F. Hunt5, Katharine F. Hunt4, Elizabeth Asztalos6, Jon Barrett6, J. Johanna Sanchez6, Alberto de Leiva, Moshe Hod7, Lois Jovanovic8, Lois Jovanovic9, Erin Keely10, Ruth McManus11, Eileen K. Hutton12, Claire L Meek13, Zoe A. Stewart13, Tim Wysocki14, Robert O'Brien, Katrina J. Ruedy, Craig Kollman, George Tomlinson1, George Tomlinson15, Helen R. Murphy16, Helen R. Murphy4, Helen R. Murphy13, Jeannie Grisoni5, Carolyn Byrne5, Katy Davenport5, Sandra L. Neoh5, Claire Gougeon3, Carolyn Oldford3, Catherine Young3, Louisa Green4, Benedetta Rossi4, Helen Rogers4, Barbara Cleave17, Michelle Strom17, J. M. Adelantado18, Ana Chico18, Diana Tundidor18, Janine Malcolm19, Kathy Henry19, Damian Morris, Gerry Rayman, Duncan Fowler, Susan Mitchell, Josephine Rosier, R. C. Temple20, Jeremy Turner20, Gioia Canciani20, Niranjala M Hewapathirana20, Leanne Piper20, Anne Kudirka, Margaret Watson, Matteo Bonomo, Basilio Pintaudi, Federico Bertuzzi, Giuseppina Daniela, Elena Mion, Julia Lowe21, Ilana Halperin21, Anna Rogowsky21, Sapida Adib21, Robert S. Lindsay22, David M. Carty22, Isobel Crawford22, Fiona Mackenzie22, Therese McSorley22, J. D. Booth12, Natalia McInnes12, Ada Smith12, Irene Stanton12, Tracy Tazzeo12, John Weisnagel23, Peter Mansell24, Nia Jones24, Gayna Babington24, Dawn Spick24, Malcolm MacDougall25, Sharon Chilton25, Terri Cutts25, Michelle Perkins25, Eleanor Scott26, Del Endersby26, Anna Dover27, Frances Dougherty27, Susan Johnston27, Simon Heller, Peter Novodorsky, Sue Hudson, Chloe Nisbet, Thomas Ransom, Jill Coolen, Darlene Baxendale, Richard I. G. Holt28, Jane Forbes28, Nicki Martin28, Fiona Walbridge28, Fidelma Dunne29, Sharon Conway29, Aoife M. Egan29, Collette Kirwin29, Michael Maresh30, Gretta Kearney30, Juliet Morris30, Susan J. Quinn30, Rudy Bilous31, Rasha Mukhtar31, Ariane Godbout, Sylvie Daigle, Alexandra Lubina32, Margaret Hadley Jackson32, Emma Paul32, Julie Taylor32, Robyn L. Houlden24, Robyn L. Houlden33, Adriana Breen24, Adriana Breen33, Anita Banerjee, Anna Brackenridge, Annette Briley, Anna Reid, Claire Singh, Jill Newstead-Angel34, Janet Baxter34, Sam Philip, Martyna Chlost, Lynne Murray, Kristin Castorino, Donna Frase, Olivia Lou35, Marlon Pragnell35 
TL;DR: In this paper, the effectiveness of continuous glucose monitoring (CGM) on maternal glucose control and obstetric and neonatal health outcomes was examined in women with Type 1 diabetes and planning pregnancy.

398 citations

Journal ArticleDOI
TL;DR: The prevalence of GDM diagnosed by the IADPSG/WHO 2013 GDM criteria in European pregnant women with a BMI ≥29.0 kg/m2 is substantial, and poses a significant health burden to these pregnancies and to the future health of the mother and her offspring.
Abstract: Accurate prevalence estimates for gestational diabetes mellitus (GDM) among pregnant women in Europe are lacking owing to the use of a multitude of diagnostic criteria and screening strategies in both high-risk women and the general pregnant population. Our aims were to report important risk factors for GDM development and calculate the prevalence of GDM in a cohort of women with BMI ≥29 kg/m2 across 11 centres in Europe using the International Association of the Diabetes and Pregnancy Study Groups (IADPSG)/WHO 2013 diagnostic criteria. Pregnant women (n = 1023, 86.3% European ethnicity) with a BMI ≥29.0 kg/m2 enrolled into the Vitamin D and Lifestyle Intervention for GDM Prevention (DALI) pilot, lifestyle and vitamin D studies of this pan-European multicentre trial, attended for an OGTT during pregnancy. Demographic, anthropometric and metabolic data were collected at enrolment and throughout pregnancy. GDM was diagnosed using IADPSG/WHO 2013 criteria. GDM treatment followed local policies. The number of women recruited per country ranged from 80 to 217, and the dropout rate was 7.1%. Overall, 39% of women developed GDM during pregnancy, with no significant differences in prevalence across countries. The prevalence of GDM was high (24%; 242/1023) in early pregnancy. Despite interventions used in the DALI study, a further 14% (94/672) had developed GDM when tested at mid gestation (24–28 weeks) and 13% (59/476) of the remaining cohort at late gestation (35–37 weeks). Demographics and lifestyle factors were similar at baseline between women with GDM and those who maintained normal glucose tolerance. Previous GDM (16.5% vs 7.9%, p = 0.002), congenital malformations (6.4% vs 3.3%, p = 0.045) and a baby with macrosomia (31.4% vs 17.9%, p = 0.001) were reported more frequently in those who developed GDM. Significant anthropometric and metabolic differences were already present in early pregnancy between women who developed GDM and those who did not. The prevalence of GDM diagnosed by the IADPSG/WHO 2013 GDM criteria in European pregnant women with a BMI ≥29.0 kg/m2 is substantial, and poses a significant health burden to these pregnancies and to the future health of the mother and her offspring. Uniform criteria for GDM diagnosis, supported by robust evidence for the benefits of treatment, are urgently needed to guide modern GDM screening and treatment strategies.

111 citations

Journal ArticleDOI
TL;DR: It is shown that in the already high-risk settings of both GDM and PGDM, excessive GWG confers an additive risk for LGA birth weight, macrosomia, and gestational hypertension.
Abstract: Context: Women who have diabetes mellitus during pregnancy are at higher risk of adverse outcomes. Excessive gestational weight gain (GWG) is also emerging as a risk factor for maternofetal complications, and in 2009, the Institute of Medicine published recommendations for appropriate GWG. It is unclear whether excessive GWG confers additional risk to women with diabetes in pregnancy and whether Institute of Medicine recommendations are applicable to this population. Objective: The objective of this study was to examine whether excessive GWG in pregnancies complicated by diabetes mellitus is associated with higher adverse obstetric outcomes. Design: This was an observational study. Setting: The study was conducted at five antenatal centers along the Irish Atlantic seaboard. Participants: 802 women with diabetes in pregnancy participated in the study. Main Outcome Measure: Maternal outcomes examined included preeclampsia, gestational hypertension, and cesarean delivery. Fetal outcomes included large for ge...

110 citations

Journal ArticleDOI
01 Feb 2006-Medicine
TL;DR: The recommended way of measuring plasma glucose and the threshold used to define what is normal or abnormal have gone through several iterations over the past two decades are reviewed in this article.

104 citations

Journal ArticleDOI
TL;DR: This study highlights the challenges facing clinicians in improving exercise levels in patients, and the need to identify the specific barriers to exercise in the individual to improve health outcomes.
Abstract: Background: Although regular exercise is a critical component of the management of type 2 diabetes, many patients do not meet their exercise targets. Lack of exercise is associated with obesity and adverse cardiovascular outcomes. Aim: We aimed to assess exercise habits in obese Irish patients with type 2 diabetes to determine if patients are adhering to exercise guidelines and to identify perceived barriers to exercise in this group. Design: A cross-sectional study of obese patients with type 2 diabetes attending routine outpatient diabetes clinics at our institution, a public teaching hospital located on the outskirts of Dublin City. Methods: A total of 145 obese patients with type 2 diabetes were administered a questionnaire to evaluate exercise habits and perceived barriers to exercise. Anthropometric details were measured. Results: About 47.6% ( n = 69) of patients exercised for <150 minutes per week (40% of males, 62% of females; P = 0.019) and these patients had a higher body mass index than those meeting targets (35 vs. 33.5 kg/m2; P = 0.02). Perceived barriers to exercise were varied, with lack of time and physical discomfort being the most common. Reported barriers to exercise varied with age, gender and marital status. Conclusions: This study highlights the challenges facing clinicians in improving exercise levels in patients, and the need to identify the specific barriers to exercise in the individual to improve health outcomes.

71 citations


Cited by
More filters
01 Jan 2014
TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Abstract: XI. STRATEGIES FOR IMPROVING DIABETES CARE D iabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. Diabetes care is complex and requires that many issues, beyond glycemic control, be addressed. A large body of evidence exists that supports a range of interventions to improve diabetes outcomes. These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care. While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as needed. For more detailed information, refer to Bode (Ed.): Medical Management of Type 1 Diabetes (1), Burant (Ed): Medical Management of Type 2 Diabetes (2), and Klingensmith (Ed): Intensive Diabetes Management (3). The recommendations included are diagnostic and therapeutic actions that are known or believed to favorably affect health outcomes of patients with diabetes. A grading system (Table 1), developed by the American Diabetes Association (ADA) and modeled after existing methods, was utilized to clarify and codify the evidence that forms the basis for the recommendations. The level of evidence that supports each recommendation is listed after each recommendation using the letters A, B, C, or E.

9,618 citations

Journal Article
TL;DR: A diagnosis of gestational diabetes mellitus (GDM) (diabetes diagnosed in the second or third trimester of pregnancy that is not clearly overt diabetes) or chemical-induced diabetes (such as in the treatment of HIV/AIDS or after organ transplantation)
Abstract: 1. Type 1 diabetes (due to b-cell destruction, usually leading to absolute insulin deficiency) 2. Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance) 3. Gestational diabetes mellitus (GDM) (diabetes diagnosed in the second or third trimester of pregnancy that is not clearly overt diabetes) 4. Specific types of diabetes due to other causes, e.g., monogenic diabetes syndromes (such as neonatal diabetes and maturity-onset diabetes of the young [MODY]), diseases of the exocrine pancreas (such as cystic fibrosis), and drugor chemical-induced diabetes (such as in the treatment of HIV/AIDS or after organ transplantation)

2,339 citations

Journal ArticleDOI
TL;DR: This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Abstract: Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

1,776 citations

Journal ArticleDOI
TL;DR: This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.
Abstract: Measurement of glycated hemoglobin (HbA1c) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA1c testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.

1,173 citations